文献速递胸部肿瘤放疗放疗物理与技术

加拿大OCOG-LUSTRE随机试验中的肺部立体定向体部放疗认证

Lung SBRT credentialing in the Canadian OCOG-LUSTRE randomized trial.
PubMed 文献 · Clin Transl Radiat Oncol · 2022-10-13

该研究报道了III期OCOG-LUSTRE试验中针对I期非小细胞肺癌的SBRT认证经验,15个加拿大中心(8个新中心、7个成熟中心)完成机构技术调查、IROC胸部模体端到端测试及勾画与计划测试。30个测试计划中10个因重大偏差需重新计划,新中心与成熟中心违规率无差异(p=0.61)。勾画误差最大为中央型臂丛(12.55±6.62 mm)和外周型血管(13.01±12.55 mm),所有计划均通过PTV覆盖和OAR约束,但剂量梯度存在变异。

要点

  • 15个中心全部完成调查和IROC模体测试,30个测试计划中10个因重大偏差需重新计划。
  • 新中心与成熟中心方案违规无差异(p=0.61)。
  • 臂丛和血管勾画误差最大,所有计划均通过PTV覆盖和OAR约束。

核心结论

  • 肺部SBRT在勾画和计划方面存在明显差异,与中心经验无关。
  • 此类认证工作对于依赖高精度放疗的研究很重要,有助于确保试验质量和结果尽可能优化。

研究设计与样本

  • III期OCOG-LUSTRE随机试验中的SBRT认证项目。
  • 15个加拿大中心参与,其中8个为新中心,7个为既往已建立(SBRT经验≥2年)的中心。
  • 认证要求包括:机构技术调查;IROC胸部模体端到端测试;使用SBRT对1个中央型和1个外周型肺癌进行勾画并完成标准化测试病例,以宿主机构作为标准进行比较。
  • 主要假设为:所有中心间尤其OAR定义存在不可接受变异;SBRT经验有限的机构更可能违反方案指南。

主要发现

  • 所有中心均成功完成调查和IROC模体测试。
  • 30个SBRT测试计划中,10个因重大偏差需要重新计划,新中心与成熟中心之间违规无差异(p=0.61)。
  • 平均勾画误差最高为中央型病例的臂丛(12.55±6.62 mm)和外周型病例的血管(13.01±12.55 mm),近端支气管树为另一变异结构(中央型2.82±0.78 mm,外周型3.27±1.06 mm)。
  • 平均Dice系数最低为臂丛(中央型0.37±0.2,外周型0.37±0.14)、近端支气管树(中央型0.77±0.06,外周型0.75±0.09)、血管(中央型0.69±0.29,外周型0.64±0.31)和食管(中央型0.74±0.04,外周型0.76±0.04)。
  • 所有计划均通过方案规定的PTV覆盖和最大/体积OAR约束,但靶区内外的剂量梯度存在变异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report on the Stereotactic Body Radiation Therapy (SBRT) credentialing experience during the Phase III Ontario Clinical Oncology Group (OCOG) LUSTRE trial for stage I non-small cell lung cancer. METHODS: Three credentialing requirements were required in this process: (a) An institutional technical survey; (b) IROC (Imaging and Radiation Oncology Core) thoracic phantom end-to-end test; and (c) Contouring and completion of standardized test cases using SBRT for one central and one peripheral lung cancer, compared against the host institution as the standard. The main hypotheses were that unacceptable variation would exist particularly in OAR definition across all centres, and that institutions with limited experience in SBRT would be more likely to violate per-protocol guidelines. RESULTS: Fifteen Canadian centres participated of which 8 were new, and 7 were previously established (≥2 years SBRT experience), and all successfully completed surveys and IROC phantom testing. Of 30 SBRT test plans, 10 required replanning due to major deviations, with no differences in violations between new and established centres (p = 0.61). Mean contouring errors were highest for brachial plexus in the central (C) case (12.55 ± 6.62 mm), and vessels in the peripheral (P) case (13.01 ± 12.55 mm), with the proximal bronchial tree (PBT) (2.82 ± 0.78 C, 3.27 ± 1.06 P) as another variable structure. Mean dice coefficients were lowest for plexus (0.37 ± 0.2 C, 0.37 ± 0.14 P), PBT (0.77 ± 0.06 C, 0.75 ± 0.09 P), vessels (0.69 ± 0.29 C, 0.64 ± 0.31 P), and esophagus (0.74 ± 0.04 C, 0.76 ± 0.04 P). All plans passed per-protocol planning target volume (PTV) coverage and maximum/volumetric organs-at-risk constraints, although variations existed in dose gradients within and outside the target. CONCLUSIONS: Clear differences exist in both contouring and planning with lung SBRT, regardless of centre experience. Such an exercise is important for studies that rely on high precision radiotherapy, and to ensure that implications on trial quality and outcomes are as optimal as possible.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Swaminath A, Wierzbicki M, Parpia S, et al. Lung SBRT credentialing in the Canadian OCOG-LUSTRE randomized trial. Clin Transl Radiat Oncol. 2022. PMID: 36275452. doi:10.1016/j.ctro.2022.10.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。